Form 4: Applied Therapeutics CEO Shoshana Shendelman Sells Shares

Applied Therapeutics CEO Shoshana Shendelman reports the disposition of shares through sales and a trust distribution.

Summary

• On August 5, 2024, Shoshana Shendelman, CEO of Applied Therapeutics, transferred 747,886 shares of common stock from a grantor retained annuity trust to a family trust she controls.
• Also on August 5, 2024, 747,886 shares were transferred to the reporting person.
• Between August 12 and August 14, 2024, Shendelman sold a total of 777,014 shares of Applied Therapeutics common stock in multiple transactions.
• The sales occurred at weighted average prices ranging from $5.93 to $6.18 per share.
• Following these transactions, Shendelman directly owns 4,690,839 shares and indirectly owns 1,870,771 shares through various trusts and entities.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the CEO selling a significant number of shares. While not inherently bad, it could raise concerns among investors.

Negatives

• The CEO sold a significant number of shares, which could be interpreted negatively by the market.

Risks

• Continued sales of shares by the CEO could put downward pressure on the stock price.
• The market may react negatively to the CEO's decision to sell a substantial portion of her holdings.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's future prospects.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, potentially impacting the stock price.
• The sales could influence investor confidence in the company's future.

Key Dates